Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials

Diabetes, Obesity and Metabolism

Volumn 19, Issue 3, 2017, Pages 436-441

  Tuttle, Katherine R ^a   McKinney, T Dwight ^b   Davidson, Jaime A ^c   Anglin, Greg ^b   Harper, Kristine D ^b   Botros, Fady T ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

clinical trial; diabetes complications; diabetic nephropathy; dulaglutide; GLP 1; type 2 diabetes

Indexed keywords

DULAGLUTIDE; EXENDIN 4; INSULIN GLARGINE; METFORMIN; PLACEBO; SITAGLIPTIN; ANTIDIABETIC AGENT; CREATININE; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); AGED; AGONISTS; ALBUMINURIA; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; GLOMERULUS FILTRATION RATE; KIDNEY FUNCTION TEST; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; URINE;

ACUTE KIDNEY INJURY; AGED; ALBUMINURIA; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CREATININE; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; INSULIN GLARGINE; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 85013989186     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12816     Document Type: Article

References (41)

1. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD. Am J Kidney Dis. 2007;49(2)(suppl 2):S12-S154.
2. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60(5):850-886.
3. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis. 2014;64(4):510-533.
4. Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1121-1127.
5. Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev. 2016 Apr 21;32(8):776-790. doi: 10.1002/dmrr.2810. Review. PMID: 27102969 [Epub ahead of print].
6. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.
7. Davidson JA, Brett J, Falahati A, Scott D. Mild renal impairment and the efficacy and safety of liraglutide. Endocr Pract. 2011;17(3):345-355.
8. Tuttle KR, Heilmann C, Hoogwerf BJ, Brown C, Anderson PW. Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes. Am J Kidney Dis. 2013;62(2):396-398.
9. Pawaskar M, Tuttle KR, Li Q, Best JH, Anderson PW. Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine. Ann Pharmacother. 2014;48(5):571-576.
10. López-Ruiz A, del Peso-Gilsanz C, Meoro-Avilés A, et al. Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers. Pharm World Sci. 2010;32(5):559-561.
11. Weise WJ, Sivanandy MS, Block CA, Comi RJ. Exenatide-associated ischemic renal failure. Diabetes Care. 2009;32(2):e22-e23.
12. Kaakeh Y, Kanjee S, Boone K, Sutton J. Liraglutide-induced acute kidney injury. Pharmacotherapy. 2012;32(1):e7-e11.
13. Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol. 2007;64(3):317-327.
14. Byetta [prescribing information]. Wilmington, DE: AstraZeneca; 2015.
15. Bydureon [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2015.
16. Lyxumia [summary of product characteristics]. Paris, France: Sanofi-Aventis Group; 2013.
17. Tanzeum [prescribing information]. Wilmington, DE: GlaxoSmithKline LLC; 2014.
18. Victoza [prescribing information]. Princeton, NJ: Novo Nordisk Inc.; 2016.
19. Von Scholten BJ, Hansen TW, Goetze JP, Persson F, Rossing P. Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. J Diabetes Complications. 2015;29(5):670-674.
20. Muskiet MH, Tonneijck L, Smits MM, et al. Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men. Diabetes Obes Metab. 2016;18(2):178-185.
21. Tonneijck L, Smits MM, Muskiet MH, et al. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2016;59(7):1412-1421.
22. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Progression of diabetic nephropathy. Kidney Int. 2001;59(2):702-709.
23. Hoefield RA, Kalra PA, Baker PG, et al. The use of eGFR and ACR to predict decline in renal function in people with diabetes. Nephrol Dial Transplant. 2011;26(3):887-892.
24. Altemtam N, Russell J, El Nahas M. A study of the natural history of diabetic kidney disease (DKD). Nephrol Dial Transplant. 2012;27(5):1847-1854.
25. Hirai A, Imamura S, Hirai K. A novel therapeutic use of glucagon-like peptide1 receptor agonist for the treatment of overt diabetic nephropathy in patients with type 2 diabetes. (Abstract). Diabetes. 2012;61(suppl 1):A240, A 943-P.
26. Mohan V, Kannan A, Jebarani S. A retrospective analysis of the effect of liraglutide in Asian Indian patients with type 2 diabetes with proteinuria. (Abstract). Diabetes. 2012;61(suppl 1):A569, A-2249-PO.
27. Fujita H, Morii T, Fujishima H, et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int. 2014;85(3):579-589.
28. Imamura S, Hirai K, Hirai A. The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients. Tohoku J Exp Med. 2013;231(1):57-61.
29. Park CW, Kim HW, Ko SH, et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol. 2007;18(4):1227-1238.
30. Tanaka T, Higashijima Y, Wada T, Nangaku M. The potential for renoprotection with incretin-based drugs. Kidney Int. 2014;86(4):701-711.
31. Moreno C, Mistry M, Roman RJ. Renal effects of glucagon-like peptide in rats. Eur J Pharmacol. 2002;434(3):163-167.
32. Gutzwiller JP, Hruz P, Huber AR, et al. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion. 2006;73:142-150.
33. Gutzwiller JP, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab. 2004;89(6):3055-3061.
34. Skov J, Dejgaard A, Frøkiær J, et al. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab. 2013;98(4):E664-E671.
35. Lovshin JA, Barnie A, DeAlmeida A, Logan A, Zinman B, Drucker DJ. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care. 2015;38(1):132-139.
36. Schlatter P, Beglinger C, Drewe J, Gutmann H. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept. 2007;141(1-3):120-128.
37. Carraro-Lacroix LR, Malnic G, Girardi AC. Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol. 2009;297(6):F1647-F1655.
38. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-322.
39. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016 Sep 15. PMID: 27633186 [Epub ahead of print].
40. Trulicity [prescribing information]. Indianapolis, IN: Lilly USA, LLC; 2015.
41. Trulicity [summary of product characteristics]. Houten, The Netherlands: Eli Lilly and Company; 2014.